Mind Medicine Q3 2023 Gaap EPS $(0.45) Beats $(0.67) Estimate
Portfolio Pulse from saritha@benzinga.com
Mind Medicine (NASDAQ:MNMD) reported Q3 2023 GAAP EPS of $(0.45), beating the analyst consensus estimate of $(0.67) by 32.84%. This represents a 19.64% increase over losses of $(0.56) per share from the same period last year.
November 02, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mind Medicine's Q3 2023 earnings beat analyst estimates, which could positively impact the company's stock in the short term.
Mind Medicine's earnings beat the analyst consensus, which is typically a positive signal for the stock. Investors may interpret this as a sign of the company's strong performance, potentially leading to increased demand for the stock and a rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100